|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
167 a.a.
|
 |
|
|
|
|
|
|
|
180 a.a.
|
 |
|
|
|
|
|
|
|
95 a.a.
|
 |
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Complex (antibody/antigen)
|
 |
|
Title:
|
 |
Complex (antibody/antigen)
|
|
Structure:
|
 |
Antibody a6. Chain: l. Fragment: fab fragment.Pepsin digestion of intact antibody. Antibody a6. Chain: h. Fragment: fab fragment.Pepsin digestion of intact antibody. Interferon-gamma receptor alpha chain. Chain: i. Fragment: n-terminal domain.
|
|
Source:
|
 |
Mus musculus. House mouse. Organism_taxid: 10090. Homo sapiens. Human. Organism_taxid: 9606. Gene: cdna. Expressed in: escherichia coli. Expression_system_taxid: 562.
|
|
Biol. unit:
|
 |
Trimer (from
)
|
|
Resolution:
|
 |
|
2.80Å
|
R-factor:
|
0.246
|
R-free:
|
0.314
|
|
|
Authors:
|
 |
F.K.Winkler,S.Sogabe
|
Key ref:
|
 |
S.Sogabe
et al.
(1997).
Neutralizing epitopes on the extracellular interferon gamma receptor (IFNgammaR) alpha-chain characterized by homolog scanning mutagenesis and X-ray crystal structure of the A6 fab-IFNgammaR1-108 complex.
J Mol Biol,
273,
882-897.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
23-Sep-97
|
Release date:
|
25-Mar-98
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P01837
(IGKC_MOUSE) -
Immunoglobulin kappa constant from Mus musculus
|
|
|
|
Seq: Struc:
|
 |
 |
 |
107 a.a.
167 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Mol Biol
273:882-897
(1997)
|
|
PubMed id:
|
|
|
|
|
| |
|
Neutralizing epitopes on the extracellular interferon gamma receptor (IFNgammaR) alpha-chain characterized by homolog scanning mutagenesis and X-ray crystal structure of the A6 fab-IFNgammaR1-108 complex.
|
|
S.Sogabe,
F.Stuart,
C.Henke,
A.Bridges,
G.Williams,
A.Birch,
F.K.Winkler,
J.A.Robinson.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The extracellular interferon gamma receptor alpha-chain comprises two
immunoglobulin-like domains, each with fibronectin type-III topology, which are
responsible for binding interferon gamma at the cell surface. The epitopes on
the human receptor recognized by three neutralizing antibodies, A6, gammaR38 and
gammaR99, have been mapped by homolog scanning mutagenesis. In this way, a loop
connecting beta-strands C and C' in the N-terminal domain was identified as a
key component of the epitopes bound by A6 and gammaR38, whereas gammaR99 binds
to the C-terminal domain in a region including strands A and B and part of the
large C'E loop. The epitope for A6 was confirmed in a crystal structure of a
complex between a recombinant N-terminal receptor domain and the Fab fragment
from A6, determined by X-ray diffraction to 2.8 A resolution. The
antibody-antigen interface buries 1662 A2 of protein surface, including 22
antibody residues from five complementarity determining regions, primarily
through interactions with the CC' surface loop of the receptor. The floor of the
antigen binding cavity is formed mainly by residues from CDR L3 and CDR H3 while
a surrounding ridge is formed by residues from all other CDRs except L2. Many
potential polar interactions, as well as 13 aromatic side-chains, four in VL,
six in VH and three in the receptor, are situated at the interface. The surface
of the receptor contacted by A6 overlaps to a large extent with that contacted
by interferon-gamma, in the ligand-receptor complex. However, the conformation
of this epitope is very different in the two complexes, demonstrating that
conformational mobility in a surface loop on this cytokine receptor permits
steric and electrostatic complementarity to two quite differently shaped binding
sites.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 3.
Figure 3. The epitopes recognized by A6 and gR38 (in red) and gR99 (in blue) on a ribbon representation of the
IFNg.IFNgR complex as determined by le Du et al. (unpublished results). IFNg (2
<
17 kDa) is shown in pink and
green, the IFNgR in white (N-terminal domain D1) and yellow (C-terminal domain D2) (see Figure 1). The red and
blue regions are those where changes are introduced in mutant 6 (CC loop) and 8 (EF loop) (red), and 13 (strand A),
14 (strand B) and 21 (C E loop) (blue) (see Table 1).
|
 |
Figure 8.
Figure 8. Residues at the A6.
IFNgR interface; on the receptor
(bottom left, grey and turquoise),
and on A6 (top right) CDR L1
(light blue), L2 (dark blue), L3
(green), CDR H1 (yellow), H2
(orange) and H3 (red) (orientation
as in Figure 5). Figure was pro-
duced using MOLMOL (Koradi
et al., 1996).
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Elsevier:
J Mol Biol
(1997,
273,
882-897)
copyright 1997.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
D.J.Diller,
C.Humblet,
X.Zhang,
and
L.M.Westerhoff
(2010).
Computational alanine scanning with linear scaling semiempirical quantum mechanical methods.
|
| |
Proteins,
78,
2329-2337.
|
 |
|
|
|
|
 |
S.Grosdidier,
and
J.Fernández-Recio
(2008).
Identification of hot-spot residues in protein-protein interactions by computational docking.
|
| |
BMC Bioinformatics,
9,
447.
|
 |
|
|
|
|
 |
C.Chiarabelli,
J.W.Vrijbloed,
R.M.Thomas,
and
P.L.Luisi
(2006).
Investigation of de novo totally random biosequences, Part I: A general method for in vitro selection of folded domains from a random polypeptide library displayed on phage.
|
| |
Chem Biodivers,
3,
827-839.
|
 |
|
|
|
|
 |
C.L.Han,
W.Zhang,
H.T.Dong,
X.Han,
and
M.Wang
(2006).
A novel gene of beta chain of the IFN-gamma receptor of Huiyang chicken: cloning, distribution, and CD assay.
|
| |
J Interferon Cytokine Res,
26,
441-448.
|
 |
|
|
|
|
 |
I.Bello-Rivero,
Y.Torrez-Ruiz,
E.Blanco-Garcés,
G.Pentón-Rol,
O.Fernández-Batista,
L.Javier-González,
H.Gerónimo-Perez,
and
P.López-Saura
(2006).
Construction, purification, and characterization of a chimeric TH1 antagonist.
|
| |
BMC Biotechnol,
6,
25.
|
 |
|
|
|
|
 |
R.J.Duquesnoy
(2006).
A structurally based approach to determine HLA compatibility at the humoral immune level.
|
| |
Hum Immunol,
67,
847-862.
|
 |
|
|
|
|
 |
G.B.Chavali,
A.C.Papageorgiou,
K.A.Olson,
J.W.Fett,
G.Hu,
R.Shapiro,
and
K.R.Acharya
(2003).
The crystal structure of human angiogenin in complex with an antitumor neutralizing antibody.
|
| |
Structure,
11,
875-885.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.C.Peter,
P.Eftekhari,
P.Billiald,
G.Wallukat,
and
J.Hoebeke
(2003).
scFv single chain antibody variable fragment as inverse agonist of the beta2-adrenergic receptor.
|
| |
J Biol Chem,
278,
36740-36747.
|
 |
|
|
|
|
 |
H.Haruyama,
S.Ito,
K.Miyadai,
T.Takahashi,
R.Kawaida,
T.Takayama,
H.Hanzawa,
T.Hata,
J.Yamaguchi,
H.Yoshida-Kato,
K.Ichikawa,
J.Ohsumi,
S.Yonehara,
and
N.Serizawa
(2002).
Humanization of the mouse anti-Fas antibody HFE7A and crystal structure of the humanized HFE7A Fab fragment.
|
| |
Biol Pharm Bull,
25,
1537-1545.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
E.Jouanguy,
S.Dupuis,
A.Pallier,
R.Döffinger,
M.C.Fondanèche,
C.Fieschi,
S.Lamhamedi-Cherradi,
F.Altare,
J.F.Emile,
P.Lutz,
P.Bordigoni,
H.Cokugras,
N.Akcakaya,
J.Landman-Parker,
J.Donnadieu,
Y.Camcioglu,
and
J.L.Casanova
(2000).
In a novel form of IFN-gamma receptor 1 deficiency, cell surface receptors fail to bind IFN-gamma.
|
| |
J Clin Invest,
105,
1429-1436.
|
 |
|
|
|
|
 |
S.Lang,
J.Xu,
F.Stuart,
R.M.Thomas,
J.W.Vrijbloed,
and
J.A.Robinson
(2000).
Analysis of antibody A6 binding to the extracellular interferon gamma receptor alpha-chain by alanine-scanning mutagenesis and random mutagenesis with phage display.
|
| |
Biochemistry,
39,
15674-15685.
|
 |
|
|
|
|
 |
Y.A.Muller,
Y.Chen,
H.W.Christinger,
B.Li,
B.C.Cunningham,
H.B.Lowman,
and
A.M.de Vos
(1998).
VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface.
|
| |
Structure,
6,
1153-1167.
|
 |
|
PDB code:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |
|